CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
BIA 9-1067 +1 moredrug
Likely dose
BIA 9-1067 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02169440
NCT02169440Phase 1Completed
CompareCT.gov

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers

Bial - Portela C S.A.·interventional·Posted Jun 23, 2014·Updated Dec 22, 2015

In Brief

A Phase 1 clinical trial evaluating BIA 9-1067 and Warfarin for Parkinson's Disease (PD). Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate CYP2C9 inhibition by BIA 9-1067 through the assessment of its effect on the pharmacokinetics of S-warfarin, a substrate of CYP2C9.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease (PD)
CountriesPortugal
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 23, 2014
Enrollment StartJun 1, 2009
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 12.0 years ago

Interventions

BIA 9-1067drug

BIA 9-1067 25 mg

Warfarindrug

Warfarin 25 mg